AI 聊天
Loading data for AVR — first visit, this takes a few seconds.

Anteris Technologies Global Corp.

AVR · NasdaqGM · USD

8.52 +0.17 (2.04%)

收盘价: Sep 14, 2026, 7:31 PM

市值
$839.1M
成交量
70.9K
下次财报日期
Nov 12, 2026

Anteris Technologies Global Corp.(AVR)股价、分析与数据

内在价值

正在加载内在价值…

分析师预测

股票预测 →

分析师预测不可用

12个月目标价 · n/a 位分析师

分析师一致意见: n/a

时间间隔:1D
正在加载K线和信号…

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收$1.01Mn/a+63.27%
每股收益(TTM)-$0,30-$0,09+50.82%

下次财报

盘中。

预估 · 升级 →

查看财报详情 →

指标

买价
5.95
市值
839M
净利润(TTM)
-104M
n/a
-1.95
n/a
-8.61
市净率(TTM)
3.34
市销率(TTM)
373.83
财报日期
Nov 12, 2026
卖价
10.57
成交量
70,925
20日均量
1,044,620
开盘价
8.32
前收盘价
8.35
日内区间
8.26 - 8.60
52周区间
3.30 - 11.05
分红
n/a
除息日
n/a

关于 Anteris Technologies Global Corp.

查看公司资料 →
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia. Medical Devices · Healthcare

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

板块 Healthcare
上市日期 Dec 13, 2024
员工人数 174
交易所 NasdaqGM
股票代码 AVR